As shown in Table 1, there were no statistically significant differences in baseline patient demographics (age or gender) between the BCL-2− and BCL-2+ subgroups nor were there differences in AML diagnosis (de novo AML vs. secondary AML) or AML risk profile (favorable, intermediate, and adverse). Here, BCL2 is linked to acute myeloid leukemia.